Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Abstract Text:

D E Sellmeyer,D M Black,L Palermo,S Greenspan,K Ensrud,J Bilezikian,C J Rosen,D E Sellmeyer,D M Black,L Palermo,S Greenspan,K Ensrud,J Bilezikian,C J Rosen,

SUMMARY: In the PaTH trial, among the 119 women randomized to parathyroid hormone PTH(1-84) and 60 to alendronate, we found much greater variation in BMD and markers in response to PTH(1-84) compared to alendronate. No baseline participant characteristic consistently predicted increased bone density response to PTH(1-84), although women with larger changes in 1,25 dihydroxyvitamin D during therapy had larger increases in BMD. INTRODUCTION: We examined variability in BMD and markers of bone turnover in response to treatment with PTH(1-84) or alendronate in the PaTH trial. METHODS: Differences in SD were examined using Levine's test for homogeneity of variance. Change in BMD across quartiles of participant characteristics was examined using ANOVA. RESULTS: We found much greater variation in response to PTH(1-84) compared to alendronate. The SD for change in cancellous spine BMD (by QCT) was 32% on PTH(1-84) compared to 13% on alendronate (p < 0.0001). The higher variability in the PTH(1-84) group was due to substantial numbers of women with large increases in BMD on PTH(1-84). Similarly, the SD of changes in markers of formation and resorption were significantly higher on PTH(1-84) than on ALN. No baseline participant characteristics predicted increased bone density response to PTH(1-84) therapy. However, change in 1,25-OH(2)D explained 16% of the variance in BMD response to PTH(1-84). CONCLUSION: There is significant variability in the skeletal response to PTH(1-84), which exceeds that observed with alendronate. Changes in 1,25-OH(2)D were related to larger gains in BMD. This finding may have implications for elucidating either the pathway by which PTH affects the skeleton or traits that result in particular responsiveness to PTH therapy.

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Publishing Authors By Initials

DE Sellmeyer,DM Black,L Palermo,S Greenspan,K Ensrud,J Bilezikian,CJ Rosen,DE Sellmeyer,DM Black,L Palermo,S Greenspan,K Ensrud,J Bilezikian,CJ Rosen,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Osteoporosis international : a journal established

VOLUME: 18

Page Numbers: 973-9

Journal Abbreviation:

ISSN: 0937-941X

DAY: 28

MONTH: 02

YEAR: 2007

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9100105

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.

AFFILIATION: Department of Medicine/Endocrinology, University of California San Francisco, San Francisco, CA, USA. dsellmeyer@psg.ucsf.edu

Country: England

AGENCY: United States NIAMS

GRANT: N01 AR92245

ACRONYM: AR

MEDLINETA: Osteoporos Int

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis Related Publications

• A 29-year-old man with subcutaneous emphysema of the neck following blunt trauma.
• A web portal that enables collaborative use of advanced medical image processing and informatics tools through the Biomedical Informatics Research Network (BIRN).
• Acute rejection in HCV-infected liver transplant recipients: The great conundrum.
• Are stem cells drugs? The regulation of stem cell research and development.
• ArsD residues Cys12, Cys13, and Cys18 form an As(III)-binding site required for arsenic metallochaperone activity.
• BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing.
• Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair.
• Critical role for Ebf1 and Ebf2 in the adipogenic transcriptional cascade.
• Diagnosis and management of laryngopharyngeal reflux disease.
• Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition.
• Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family.
• Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
• Fibroblast growth factor-10 prevents H2O2-induced cell cycle arrest by regulation of G1 cyclins and cyclin dependent kinases.
• Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8.
• Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.
• I(Kr) contributes to the altered ventricular repolarization that determines long-term cardiac memory.
• Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum.
• Induction, characterization, and functional coupling of the high affinity chemokine receptor for RANTES and macrophage inflammatory protein-1 alpha upon differentiation of an eosinophilic HL-60 cell line.
• Integration is as essential as balance.
• Integration of prolactin and glucocorticoid signaling at the beta-casein promoter and enhancer by ordered recruitment of specific transcription factors and chromatin modifiers.
• Linking cost sharing to value: an unrivaled yet unrealized public health opportunity.
• Long-term cardiac memory in canine heart is associated with the evolution of a transmural repolarization gradient.
• Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence.
• Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics.
• Measuring the activities of the Sulfs: two novel heparin/heparan sulfate endosulfatases.
• Mouse and human granzyme B have distinct tetrapeptide specificities and abilities to recruit the bid pathway.
• Pre-clinical testing of a phased array ultrasound system for MRI-guided noninvasive surgery of the brain--a primate study.
• Stop! In the name of transforming growth factor-beta: keeping estrogen receptor-alpha-positive mammary epithelial cells from proliferating.
• Sulfated L-selectin ligands as a therapeutic target in chronic inflammation.
• The effects of aging on the bone inductive activity of recombinant human bone morphogenetic protein-2.